Helping Guide Your Early-Stage Breast Cancer Treatment Decisions.
Get a discussion guide for the Oncotype DX breast cancer test.
...About Oncotype DX
and Personalized Treatment
for Breast Cancer
Learn about a new test for patients with ductal carcinoma in situ (DCIS), or pre-invasive breast cancer
Ductal Carcinoma in situ (DCIS), or Estrogen Receptor Positive (ER+)
The information presented on this site is intended to provide patients with newly diagnosed invasive or pre-invasive breast cancer (medically known as Ductal Carcinoma In Situ), as well as their friends and family, an opportunity to hear how others have incorporated the information provided by the Oncotype DX® Recurrence Score® in making treatment decisions with their doctors. The personal stories featured on this site selected by Genomic Health, Inc., which offers the Oncotype DX® tests, are not intended to be representative of patients with breast cancer generally, and should not be considered medical advice. Patients should consult their doctor to determine the best treatment decision for their individual disease.
American Society of Clinical Oncology (ASCO) and ASCO are registered trademarks of ASCO; National Comprehensive Cancer Network (NCCN) and NCCN are registered trademarks of NCCN. ASCO and NCCN do not endorse any product or therapy.
Copyright © 2004-2013 Genomic Health, Inc. All rights reserved. Genomic Health, Oncotype, Oncotype DX, Recurrence Score, and Pass It On: Until Every Woman Knows are trademarks of Genomic Health Inc. MyBreastCancerTreatment.org is sponsored by Genomic Health, Inc., a clinical laboratory in Redwood City, California that developed and offers the Oncotype DX® Breast Cancer Assay. Genomic Health is responsible for the content of MyBreastCancerTreatment.org.